Jane Street
AMLX icon

Jane Street’s Amylyx Pharmaceuticals AMLX Stock Holding History

Jane Street’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$314K Buy
17,500
+3,800
+28% +$58.8K ﹤0.01% 9121
2026
Q1 		$190K Sell
13,700
-17,400
-56% -$245K ﹤0.01% 10197
2025
Q4 		$376K Sell
31,100
-21,400
-41% -$291K ﹤0.01% 8339
2025
Q3 		$713K Buy
+52,500
New +$494K ﹤0.01% 7055
2024
Q2 		– Sell
-260,500
Closed -$740K – 9276
2024
Q1 		$740K Buy
260,500
+39,000
+18% +$510K ﹤0.01% 5985
2023
Q4 		$3.26M Sell
221,500
-56,900
-20% -$872K ﹤0.01% 3508
2023
Q3 		$5.1M Buy
278,400
+33,800
+14% +$715K ﹤0.01% 2586
2023
Q2 		$5.28M Sell
244,600
-30,100
-11% -$813K ﹤0.01% 2657
2023
Q1 		$8.06M Buy
274,700
+145,900
+113% +$5.07M ﹤0.01% 1861
2022
Q4 		$4.76M Sell
128,800
-40,200
-24% -$1.43M ﹤0.01% 2557
2022
Q3 		$4.76M Buy
169,000
+146,200
+641% +$3.65M ﹤0.01% 2711
2022
Q2 		$439K Buy
+22,800
New +$271K ﹤0.01% 6966

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jane Street's AMLX Position: Q2 2026 in Review

Jane Street opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 299,565 shares worth $5.38M. The stake represents ﹤0.01% of the portfolio and ranks #3609 among its holdings. This is a return to the name: Jane Street previously reported a position in AMLX as recently as Q4 2025.

Jane Street first reported a position in AMLX in Q1 2022 and has held it in 15 quarters since. The position peaked at $17M in Q4 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Jane Street held 299,565 shares of Amylyx Pharmaceuticals worth $5.38M as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Jane Street position in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #3609 holding.
  • Jane Street first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
  • Jane Street's Amylyx Pharmaceuticals position peaked at $17M in Q4 2023.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.